Alkem Laboratories has provided an update on the acquisition of Occlutech Holding AG. M/s. Alkem Medtech Private Limited, a wholly owned subsidiary, has executed a First Supplementary Agreement to the Share Purchase Agreement. This follows earlier intimations regarding the intent to acquire between 51% and 55% of Occlutech’s equity share capital. The supplementary agreement further details the terms of this significant transaction.
Acquisition of Occlutech Holding AG – Further Developments
This announcement serves as a continuation of previous communications regarding the acquisition of Occlutech Holding AG by Alkem Laboratories. Alkem Medtech Private Limited, a subsidiary of Alkem Laboratories, had previously informed of its intention to acquire a substantial stake, ranging from 51% to 55%, in the equity share capital of Occlutech Holding AG, a Swiss-incorporated entity.
Supplementary Agreement Executed
In a key development, Alkem Medtech has executed a First Supplementary Agreement to the Share Purchase Agreement that was initially dated 6th March 2026. This supplementary agreement was executed on 26th June 2026 with the selling shareholders of Occlutech. This step signifies further progress in finalizing the acquisition details and moving towards the completion of the transaction.
Disclosure and Record Keeping
A copy of this disclosure will be made available on the Company’s website. Alkem Laboratories requests that the stock exchanges take this information on record. The company expresses its commitment to transparency and timely dissemination of material information to its stakeholders.
Manish Narang, President – Legal, Company Secretary & Compliance Officer, has duly authorized this disclosure.
Source: BSE
